roniciclib

an antineoplastic agent that inhibits cyclin-dependent kinases; structure in first source

Also Known As:

BAY 1000394; S-cyclopropyl-S-(4-((4-((2-hydroxy-1-methylpropyl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)sulfoximide

Networked: 14 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - roniciclib: 14
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfoxides: 23
    - roniciclib: 14

Experts

1.	Barlesi, Fabrice: 3 articles (01/2019 - 06/2017)
2.	Govindan, Ramaswamy: 3 articles (01/2019 - 06/2017)
3.	Chou, Ting-Chao: 3 articles (10/2018 - 09/2017)
4.	Hsueh, Chuen: 3 articles (10/2018 - 09/2017)
5.	Lin, Jen-Der: 3 articles (10/2018 - 09/2017)
6.	Lin, Shu-Fu: 3 articles (10/2018 - 09/2017)
7.	Wong, Richard J: 3 articles (10/2018 - 09/2017)
8.	Siemeister, Gerhard: 3 articles (01/2018 - 07/2013)
9.	Lücking, Ulrich: 3 articles (01/2017 - 07/2013)
10.	Dy, Grace K: 2 articles (01/2018 - 06/2017)

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2018 - "Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer." 01/01/2019 - "Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer." 01/01/2018 - "This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC). "
2.	Neoplasms (Cancer) 10/01/2018 - "Roniciclib treatment in vivo retarded the growth of two well-differentiated thyroid tumors in xenograft models in a dose-dependent fashion. " 06/06/2017 - "To evaluate safety, pharmacokinetics, and maximum tolerated dose of roniciclib in patients with advanced malignancies, with dose expansion to evaluate clinical benefit at the recommended phase II dose (RP2D). " 07/01/2013 - "The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer." 06/15/2018 - "In vivo, roniciclib treatment retarded the growth of tumors of medullary thyroid cancer xenografts. " 09/15/2017 - "In vivo, the growth of anaplastic thyroid cancer xenograft tumors was retarded by roniciclib treatment without evidence of toxicity. "
3.	Thyroid Neoplasms (Thyroid Cancer) 10/01/2018 - "These findings support roniciclib as a potential drug for the treatment of patients with well-differentiated thyroid cancer." 10/01/2018 - "Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer." 10/01/2018 - "The therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor for papillary and follicular thyroid cancer (designated as well-differentiated thyroid cancer), were investigated in this study. "
4.	follicular Thyroid cancer 10/01/2018 - "Roniciclib inhibited cell proliferation in two papillary and two follicular thyroid cancer cell lines in a dose-dependent manner. " 10/01/2018 - "Furthermore, the combination of roniciclib with sorafenib was more effective than either single treatment in a follicular thyroid cancer xenograft model. " 10/01/2018 - "The therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor for papillary and follicular thyroid cancer (designated as well-differentiated thyroid cancer), were investigated in this study. "
5.	medullary Thyroid cancer 06/15/2018 - "These data provide a rationale for clinical assessment of using roniciclib in the treatment of patients with medullary thyroid cancer." 06/15/2018 - "Roniciclib inhibited medullary thyroid cancer cell proliferation in a dose-dependent manner. " 06/15/2018 - "Activity of roniciclib in medullary thyroid cancer." 06/15/2018 - "In vivo, roniciclib treatment retarded the growth of tumors of medullary thyroid cancer xenografts. " 06/15/2018 - "The therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor for medullary thyroid cancer were investigated in the present study. "

Related Drugs and Biologics

1.	Cyclin-Dependent Kinases (cdk Proteins)
2.	Cisplatin (Platino)
3.	Carboplatin (JM8)
4.	Etoposide (VP 16)
5.	Therapeutic Uses
6.	Roscovitine
7.	14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaene
8.	dinaciclib
9.	RGB 286638
10.	4- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamide

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)